Page last updated: 2024-11-11

cyhexatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyhexatin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6327054
CHEBI ID4036
SCHEMBL ID26095
MeSH IDM0042089

Synonyms (48)

Synonym
hydroxytricyclohexylstannane
tricyclohexylhydroxytin
m 3180
stannane, tricyclohexylhydroxy-
tricyclohexylhydroxystannane
nsc-179742
plyctran
tricyclohexyltin hydroxide
tricyclohexylzinnhydroxid
nsc179742
plictran
wln: l6tj a-sn-q- al6tj&- al6tj
tin, tricyclohexylhydroxy-
dowco 213
ent 27,395-x
tcth
cyhexatin
13121-70-5
CHEBI:4036 ,
tricyclohexylstannanol
tricyclohexylstannium hydroxide
NCGC00164294-01
plictran 5ow miticide
tricyclohexylzinnhydroxid [german]
ent 27395
ortho plictran 50 wettable miticide
cyhexatin [ansi:bsi:iso]
hsdb 1782
einecs 236-049-1
nsc 179742
ccris 6824
epa pesticide chemical code 101601
dowco-213
caswell no. 884a
8yjv11qb4r ,
unii-8yjv11qb4r
AKOS015904131
cyhexatin [iso]
cyhexatin [mi]
cyhexatin [hsdb]
SCHEMBL26095
DTXSID1032357
tricyclohexyltin;hydrate
cyhexatin, pestanal(r), analytical standard
mfcd00078642
J-005963
cid 25199838
?cyhexatin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Female animals showed increased sensitivity to the toxic effects by DNOC at the highest dose."( Genetic safety evaluation of pesticides in different short-term tests.
Cantelli-Forti, G; Colacci, A; Grilli, S; Hrelia, P; Maffei, F; Morotti, M; Perocco, P; Vigagni, F, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
"5 h following exposure, the mice dosed with the two higher levels of TCT or TPhT exhibited increases in MES severity."( Effects of organotin compounds on maximal electroshock seizure (MES) responsiveness in mice. II. Tricyclohexyltin and triphenyltin.
Doctor, SV; Fox, DA, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency39.81070.025127.9203501.1870AID651751
AR proteinHomo sapiens (human)Potency12.67280.000221.22318,912.5098AID588515; AID588516
retinoid X nuclear receptor alphaHomo sapiens (human)Potency8.32160.000817.505159.3239AID588544; AID588546
farnesoid X nuclear receptorHomo sapiens (human)Potency25.11890.375827.485161.6524AID588526
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.89370.000229.305416,493.5996AID588513; AID588514
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency42.20900.001024.504861.6448AID588534; AID588535
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency15.64980.023723.228263.5986AID588541; AID588543
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency14.12540.010039.53711,122.0200AID588547
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency31.62284.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.50830.000627.21521,122.0200AID651741; AID720636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (56.67)18.7374
1990's6 (20.00)18.2507
2000's4 (13.33)29.6817
2010's2 (6.67)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.59 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]